Metabolic regulation: effects of natriuretic peptide interactions

References

• de Bold AJ, Borenstein HB, Veress AT et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Reprinted from Life Sci.28, 89–94 (1981). J. Am. Soc. Nephrol.12, 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• de Bold AJ, Borenstein HB, Veress AT et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci.28, 89–94 (1981).
   PubMed Web of Science ®Google Scholar
• Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev.27, 47–72 (2006).
   PubMed Web of Science ®Google Scholar
• Yang-Feng TL, Floyd-Smith G, Nemer M et al. The pronatriodilatin gene is located on the distal short arm of human chromosome 1 and on mouse chromosome 4. Am. J. Hum. Genet.37, 1117–1128 (1985).
   PubMed Web of Science ®Google Scholar
• Sudoh T, Kangawa K, Minamino N et al. A new natriuretic peptide in porcine brain. Nature332, 78–81 (1988).
   PubMed Web of Science ®Google Scholar
• Potter LR, Garbers DL. Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization. J. Biol. Chem.267, 14531–14534 (1992).
   PubMed Web of Science ®Google Scholar
• Kuhn M, Voss M, Mitko D et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. Cardiovasc. Res.64, 308–314 (2004).
   PubMed Web of Science ®Google Scholar
• Haneda M, Kikkawa R, Maeda S et al. Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int.40, 188–194 (1991).
   PubMed Web of Science ®Google Scholar
• Abbey SE, Potter LR. Vasopressin-dependent inhibition of the C-type natriuretic peptide receptor, NPR-B/GC-B, requires elevated intracellular calcium concentrations. J. Biol. Chem.277, 42423–42430 (2002).
   PubMed Web of Science ®Google Scholar
• Sarzani R, Dessi-Fulgheri P, Paci VM et al. Expression of natriuretic peptide receptors in human adipose and other tissues. J. Endocrinol. Invest.19, 581–585 (1996).
   PubMed Web of Science ®Google Scholar
• Schulz S, Singh S, Bellet RA et al. The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family. Cell58, 1155–1162 (1989).
   PubMed Web of Science ®Google Scholar
• Suga S, Nakao K, Hosoda K et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology130, 229–239 (1992).
   PubMed Web of Science ®Google Scholar
• Pagano M, Anand-Srivastava MB. Cytoplasmic domain of natriuretic peptide receptor C constitutes Gi activator sequences that inhibit adenylyl cyclase activity. J. Biol. Chem.276, 22064–22070 (2001).
   PubMed Web of Science ®Google Scholar
• Anand-Srivastava MB, Sehl PD, Lowe DG. Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a pertussis toxin-sensitive G protein. J. Biol. Chem.271, 19324–19329 (1996).
   PubMed Web of Science ®Google Scholar
• Jaubert J, Jaubert F, Martin N et al. Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). Proc. Natl Acad. Sci. USA96, 10278–10283 (1999).
   PubMed Web of Science ®Google Scholar
• Matsukawa N, Grzesik WJ, Takahashi N et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc. Natl Acad. Sci. USA96, 7403–7408 (1999).
   PubMed Web of Science ®Google Scholar
• Charles CJ, Espiner EA, Nicholls MG et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am. J. Physiol.271, R373–R380 (1996).
   PubMedGoogle Scholar
• Edwards BS, Zimmerman RS, Schwab TR et al. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ. Res.62, 191–195 (1988).
   PubMed Web of Science ®Google Scholar
• Engelmann MD, Niemann L, Kanstrup IL et al. Natriuretic peptide response to dynamic exercise in patients with atrial fibrillation. Int. J. Cardiol.105, 31–39 (2005).
   PubMed Web of Science ®Google Scholar
• Moro C, Crampes F, Sengenes C et al. Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J.18, 908–910 (2004).
   PubMed Web of Science ®Google Scholar
• Ogihara T, Shima J, Hara H et al. Significant increase in plasma immunoreactive atrial natriuretic polypeptide concentration during head-out water immersion. Life Sci.38, 2413–2418 (1986).
   PubMed Web of Science ®Google Scholar
• Hollister AS, Tanaka I, Imada T et al. Sodium loading and posture modulate human atrial natriuretic factor plasma levels. Hypertension8, II106–II111 (1986).
   PubMedGoogle Scholar
• Cody RJ, Atlas SA, Laragh JH et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J. Clin. Invest.78, 1362–1374 (1986).
   PubMed Web of Science ®Google Scholar
• Mukoyama M, Nakao K, Hosoda K et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest.87, 1402–1412 (1991).
   PubMed Web of Science ®Google Scholar
• McCullough PA, Nowak RM, McCord J et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study. Circulation106, 416–422 (2002).
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA287, 1531–1540 (2002).
   PubMed Web of Science ®Google Scholar
• Sengenes C, Berlan M et al. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J.14, 1345–1351 (2000).
   PubMed Web of Science ®Google Scholar
• Moro C, Galitzky J, Sengenes C et al. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J. Pharmacol. Exp. Ther.308, 984–992 (2004).
   PubMed Web of Science ®Google Scholar
• Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J. Biol. Chem.272, 6823–6826 (1997).
   PubMed Web of Science ®Google Scholar
• Boschmann M. Heterogenity of adipose tissue metabolism. In: Adipose Tissue. Klaus S (Ed.). Landes Bioscience, CO, USA 131–157 (2001).
   Google Scholar
• Birkenfeld AL, Boschmann M, Moro C et al. β-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation. J. Clin. Endocrinol. Metab.91, 5069–5075 (2006).
   PubMed Web of Science ®Google Scholar
• Sengenes C, Bouloumie A, Hauner H et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J. Biol. Chem.278, 48617–48626 (2003).
   PubMed Web of Science ®Google Scholar
• Khoo JC, Sperry PJ, Gill GN et al. Activation of hormone-sensitive lipase and phosphorylase kinase by purified cyclic GMP-dependent protein kinase. Proc. Natl Acad. Sci. USA74, 4843–4847 (1977).
   PubMed Web of Science ®Google Scholar
• Sengenes C, Zakaroff-Girard A, Moulin A et al. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am. J. Physiol. Regul. Integr. Comp. Physiol.283, R257–R265 (2002).
   PubMed Web of Science ®Google Scholar
• Birkenfeld AL, Boschmann M, Moro C et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J. Clin. Endocrinol. Metab.90, 3622–3628 (2005).
   PubMed Web of Science ®Google Scholar
• Uehlinger DE, Weidmann P, Gnadinger MP et al. Increase in circulating insulin induced by atrial natriuretic peptide in normal humans. J. Cardiovasc. Pharmacol.8, 1122–1129 (1986).
   PubMed Web of Science ®Google Scholar
• Moro C, Polak J, Richterova B et al. Differential regulation of atrial natriuretic peptide- and adrenergic receptor-dependent lipolytic pathways in human adipose tissue. Metabolism54, 122–131 (2005).
   PubMed Web of Science ®Google Scholar
• Floras JS. Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation81, 1860–1873 (1990).
   PubMed Web of Science ®Google Scholar
• Lang CC, Struthers AD. Interactions between atrial natriuretic factor and the autonomic nervous system. Clin. Auton. Res.1, 329–336 (1991).
   PubMedGoogle Scholar
• Galitzky J, Sengenes C, Thalamas C et al. The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J. Lipid Res.42, 536–544 (2001).
   PubMed Web of Science ®Google Scholar
• Rashed HM, Nair BG, Patel TB. Regulation of hepatic glycolysis and gluconeogenesis by atrial natriuretic peptide. Arch. Biochem. Biophys.298, 640–645 (1992).
   PubMed Web of Science ®Google Scholar
• Tunstall RJ, Cameron-Smith D. Effect of elevated lipid concentrations on human skeletal muscle gene expression. Metabolism54, 952–959 (2005).
   PubMed Web of Science ®Google Scholar
• Moro C, Klimcakova E, Lolmede K et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia50, 1038–1047 (2007).
   PubMed Web of Science ®Google Scholar
• Kiemer AK, Hartung T, Vollmar AM. cGMP-mediated inhibition of TNF-α production by the atrial natriuretic peptide in murine macrophages. J. Immunol.165, 175–181 (2000).
   PubMed Web of Science ®Google Scholar
• Kiemer AK, Lehner MD, Hartung T et al. Inhibition of cyclooxygenase-2 by natriuretic peptides. Endocrinology143, 846–852 (2002).
   PubMed Web of Science ®Google Scholar
• Weber NC, Blumenthal SB, Hartung T et al. ANP inhibits TNF-α-induced endothelial MCP-1 expression – involvement of p38 MAPK and MKP-1. J. Leukoc. Biol.74, 932–941 (2003).
   PubMed Web of Science ®Google Scholar
• Fain JN, Kanu A, Bahouth SW et al. Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes. Biochem. Pharmacol.65, 1883–1888 (2003).
   PubMed Web of Science ®Google Scholar
• Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation112, 1756–1762 (2005).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation109, 594–600 (2004).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Keyes MJ et al. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation115, 1345–1353 (2007).
   PubMed Web of Science ®Google Scholar
• Igaki T, Itoh H, Suga S et al. C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney Int. Suppl.55, S144–S147 (1996).
   Google Scholar
• Cogan E, Debieve MF, Philipart I et al. High plasma levels of atrial natriuretic factor in SIADH. N. Engl. J. Med.314, 1258–1259 (1986).
   PubMed Web of Science ®Google Scholar
• La Villa G, Romanelli RG, Casini R et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology16, 156–161 (1992).
   PubMed Web of Science ®Google Scholar
• Chen YF. Atrial natriuretic peptide in hypoxia. Peptides26, 1068–1077 (2005).
   PubMed Web of Science ®Google Scholar
• Tan AC, Russel FG, Thien T et al. Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet.24, 28–45 (1993).
   PubMed Web of Science ®Google Scholar
• Singh G, Kuc RE, Maguire JJ et al. Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure. Circ. Res.99, 183–190 (2006).
   PubMed Web of Science ®Google Scholar
• Moro C, Polak J, Hejnova J et al. Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise. Am. J. Physiol. Endocrinol. Metab.290, E864–E869 (2006).
   Google Scholar
• Moro C, Pillard F, De G, I et al. Training enhances ANP lipid-mobilizing action in adipose tissue of overweight men. Med. Sci. Sports Exerc.37, 1126–1132 (2005).
   PubMed Web of Science ®Google Scholar
• Depre C, Shipley GL, Chen W et al. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat. Med.4, 1269–1275 (1998).
   PubMed Web of Science ®Google Scholar
• Tuunanen H, Engblom E, Naum A et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation114, 2130–2137 (2006).
   PubMed Web of Science ®Google Scholar
• Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet349, 1050–1053 (1997).
   PubMed Web of Science ®Google Scholar
• von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc. Res.73, 298–309 (2007).
   PubMed Web of Science ®Google Scholar
• McEntegart MB, Awede B, Petrie MC et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J.28(7), 829–835 (2007).
   PubMedGoogle Scholar
• Dessi-Fulgheri P, Sarzani R, Tamburrini P et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J. Hypertens.15, 1695–1699 (1997).
   PubMed Web of Science ®Google Scholar
• Licata G, Volpe M, Scaglione R et al. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension23, I20–I24 (1994).
   Google Scholar
• Sarzani R, Strazzullo P, Salvi F et al. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes. Res.12, 351–356 (2004).
   PubMedGoogle Scholar
• Sengenes C, Stich V, Berlan M et al. Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low-calorie diet in obese women. Int. J. Obes. Relat. Metab. Disord.26, 24–32 (2002).
   PubMed Web of Science ®Google Scholar
• Sarzani R, Paci VM, Zingaretti CM et al. Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. J. Hypertens.13, 1241–1246 (1995).
   PubMed Web of Science ®Google Scholar
• Olsen MH, Hansen TW, Christensen MK et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension46, 660–666 (2005).
   PubMed Web of Science ®Google Scholar
• Lafontan M, Moro C, Sengenes C, Galitzky J, Crampes F, Berlan M. An unsuspected metabolic role for atrial natriuretic peptides: the control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans. Aterioscler. Thromb. Vasc. Biol.25, 2032–2042 (2005).
   Google Scholar